Diabetes

PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.

ANAHEIM, Calif. — Patients with insulin allergy were treated successfully with omalizumab, rituximab and/or mycophenolate, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

NASHVILLE, Tenn. — Diabetes appeared linked to shorter survival among patients who underwent nephrectomy for renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium: North America.

According to Prevent Blindness, more than 26% of people with diabetes have diabetic retinopathy, the most common diabetes-related eye disease and the primary cause of blindness in adults aged 20 to 74 years.

The total annual cost of caring for Americans with diabetes in 2022 was an estimated $412.9 billion, and one in four total health care dollars in the U.S. went toward diabetes care, according to a report.

The recommendation that people living with diabetes should avoid carbohydrates is misguided, according to a speaker at the Lifestyle Medicine Conference.

The FDA issued a warning for consumers to avoid using a nonprescription product currently being sold for blood glucose management due to risks for adverse events, according to an agency press release.

College graduates may have lower CV risk in middle and older age compared with individuals who did not complete college or high school earlier in life, researchers reported.

Healio and Cardiology Today have aggregated news you may have missed from the 2023 Cardiometabolic Health Congress in Boston.

PHILADELPHIA — A novel aldosterone synthase inhibitor, BI 690517, was well-tolerated and reduced urine albumin-to-creatinine ratio in patients with chronic kidney disease, according to a presentation at ASN Kidney Week.